Alterity reports positive trial results
Alterity reports positive topline data from open-label phase II trial of ATH434 in multiple system atrophy
ATH434 demonstrated clinical benefit on Unified MSA Rating Scale and global measures of neurological symptoms
Neuroimaging biomarkers showed target engagement and slowed brain atrophy with drug well tolerated and having a favourable safety profile
The study, conducted in a patient population with more advanced disease than in the Alterity Therapeutics' (ASX:ATH) double-blind phase II trial, showed ATH434 was well tolerated and provided measurable clinical benefits, including stabilisation of neurological symptoms and slowed brain atrophy.
Over the 12-month treatment period, results indicated patients treated with ATH434 showed ~50% less disease progression on the Modified Unified MSA Rating Scale (UMSARS I) compared to historical controls.
Notably, 30% of participants reported stable or improved symptoms – an uncommon result in this advanced patient group.
In further encouraging results, 30% of participants also stabilised or improved on the Patient Global Impression of Change (PGIC) scale, which asks the patient to evaluate their overall neurological symptoms as compared to immediately before starting therapy.
ATH434 also helped stabilise symptoms of orthostatic hypotension, a common and serious drop in blood pressure when standing, in study participants.
Notably, the overall results suggest that ATH434 was just as effective in this more advanced group of MSA patients as it was in earlier-stage patients from the previous phase II double-blinded trial.
Neuroimaging data provided further support, showing a slowing of brain volume loss in MSA-affected regions and reduced iron accumulation – both consistent with the proposed mechanism of ATH434, which targets excess brain iron thought to drive MSA pathology.
Novel approach could provide much-needed therapy
Alterity's lead indication, MSA, is a rare and aggressive parkinsonian disorder with up to 50,000 patients in the US, driven by excess iron and aggregation of a protein called alpha-synuclein in the central nervous system.
ATH434 takes a novel approach to MSA by addressing iron imbalance and protein aggregation, offering what could be the first disease-modifying therapy.
The drug has been granted both fast track and orphan drug designations by the US Food and Drug Administration, as well as orphan drug status in the EU.
Backed by promising phase II and open-label phase II results, Alterity is chasing a market opportunity exceeding US$1.1 billion with ATH434.
About the open-label study
The phase II open label trial (ATH-434-202) was an open-label study in advanced MSA.
The trial enrolled participants diagnosed with MSA using a multimodal approach (clinical, neuroimaging, fluid biomarkers), who were treated with oral ATH434 75mg twice daily for 12 months.
The study assessed the safety and efficacy of ATH434 treatment on clinical and biomarker endpoints.
The pre-specified key clinical endpoints included the modified UMSARS I, the clinical global impression of change, and the patient global impression of change.
Enrolled participants were more advanced than those in the double-blind ATH434-201 phase II trial based on baseline variables including duration of motor symptoms, UMSARS I score, frequency of severe orthostatic hypotension, and plasma NFL levels.
Based on the observed clinical and neuroimaging data, ATH434 improved overall neurological symptoms and slowed disease progression compared to historical data.
'Strongly support advancing our ATH434 program'
CEO Dr David Stamler said he was very encouraged by the positive results from the ATH434-202 trial, as they reinforce the robust efficacy we observed in its phase II study.
'The data from our phase II studies are consistent and strongly support advancing our ATH434 program in MSA,' he said.
'With the favourable clinical and biomarker outcomes we have seen, we continue to believe that ATH434 has the potential to slow the progression of this devastating disease.
'We are committed to bringing this new therapy to patients as soon as possible.'
The trial's lead investigator, professor Daniel Claassen from Vanderbilt University Medical Centre said the results were very helpful in establishing the clinical response to therapy.
He said the consistent changes in UMSARS, along with quantitative measures in imaging, support the findings noted in the phase II trial.
'Currently, there are no disease modifying medications for the treatment of MSA, and these data encourage the continued development of ATH434 to treat this disease,' he said.
'We are indebted to the study participants and their families who contributed to this study.'
This article was developed in collaboration with Alterity Therapeutics, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
24 minutes ago
- ABC News
What can we learn from New Zealand's experience with potato mop-top virus?
For the first time, potato mop-top virus has been detected in Australia. Spread by a soil-borne fungus vector that can cling to machinery and other materials, it's so far unclear how the disease made it onto a farm in north-west Tasmania. An incident management team has been created to trace and contain the virus, amid concerns for the state's $300 million potato industry. Seven years ago, one of Australia's closest neighbours was dealing with a detection of the same virus. So what can Tasmania learn from the experience across the ditch? Potato mop-top virus was first recorded in a single potato tuber taken from the storage facility of a processing factory in Canterbury, New Zealand in September 2018. Before then, the disease had never been seen in New Zealand. In Tasmania, the virus has only been detected on one farm and risk mitigation measures have been put in place to try and contain it. But in New Zealand, it wasn't clear exactly which paddock the diseased tuber had come from, so a range of sites were tested and it soon became clear the virus was in several paddocks in Canterbury. Iain Kirkwood, an agronomist and biosecurity manager from industry group Potatoes New Zealand, said an international committee of experts was set up to look at response options in New Zealand. "They very quickly came to the conclusion that we cannot eradicate it, because it's a soil-borne organism which causes a powdery scab, and that can stay in the soil for years and years," Dr Kirkwood said. According to the advisory group, eradication had not been achieved in many other international regions where the virus had been recorded either. The New Zealand response moved from "eradication" to "management". Dr Kirkwood said an entire department of the Ministry for Primary Industries looks at tracking and tracing how various incursions get into the country, but, despite a lot of time and money, it couldn't determine how potato mop-top virus arrived in New Zealand. Potato mop-top virus is also found in the United States. Professor Alexander Karasev from the University of Idaho said it might be difficult to trace how the virus entered Tasmania. "In the US, we suspect that the main route of transmission of the virus is with soil … that might be potted for ornamental [plants] which may not even be related to potatoes," Professor Karasev said. Potato mop-top virus can cause significant yield and quality reductions in potatoes. Dr Kirkwood said there hadn't been any reports of yield impacts in New Zealand. He said the virus was discovered in one seed paddock, and that seed line had to be destroyed and the grower compensated. But he said overall, there hadn't been a major impact on New Zealand's potato industry so far. "We're monitoring it through the processors — they report to us if they see mop-top in their lines — and they're recording it every so often," Dr Kirkwood said. "But it's not causing any significant economic impact either on the growers or the processors right now." The international expert advisory group did give New Zealand a warning, though. "We're hopefully monitoring it sufficiently and that it's not going to creep up upon and cause some major issues, but it's one that you do have to pay attention to." Dr Kirkwood said the most important thing New Zealand did was an early survey, testing about 200 lines of potatoes, including seed potatoes, throughout the whole country, to get a good picture of where and how widespread the virus was. "It's very difficult to carry out a response if you're not certain as to where the disease actually is, so I would encourage Tasmania to do some form of survey," he said. Dr Kirkwood also said it would be important for Biosecurity Tasmania to work with the local industry. "The local industry knows the industry better than anyone else — far better than Biosecurity Tasmania does — so I would encourage them to work closely with the growers and the grower organisations."
News.com.au
an hour ago
- News.com.au
Health Check: Pro Medicus banks the profits as customers go the ‘full stack'
Pro Medicus shares surge up to 7% on record revenue and earnings Tetratherix pockets $3.3 million, while Rhythm girds for a raising CEO oration inspires Starpharma share run The $32 billion market cap ProMedicus (ASX:PME) has drawn the chapter on what co-founder and CEO Dr Sam Hupert dubs 'the most successful year in the company's history by any measure'. The US-focused radiology imaging house today posted revenue of $213 million for the full year to June 30 2025, up 32%. Net earnings surged 39%, to $115 million. While the numbers were pretty much as expected, the shares surged up to 7% on the prospect of further revenue gains from newly-written contracts. The company is also expanding into areas such as cardiology and pathology – the latter of which could be two-thirds the size of the radiology market. "But it's early days." Hupert describes a 'record year of new contract wins, contract renewals and sales of additional modules'. Revenue rose in the three key jurisdictions of the US, Germany and Australia, but North America led the way with a 36% increase. The company derives about 90% of its revenue from the US. During the year, Pro Medicus won $520 million of new contracts. Yep, that's a record. These included a monster $330 million deal with Trinity Health, one of the biggest not-for-profit networks in the US. The company also signed two key renewals, totalling $130 million. Hupert says more customers are going the 'full stack', which means they are availing of the company's image viewing, archiving and workflow tools. Only the beginning? He adds that many of the recently signed contacts will come on stream 'in the next year and beyond', which means 98% of this revenue is yet to be recognised. He cites forward contracted revenue for the next five years at $948 million, up from $624 million a year ago. Despite the growth, Pro Medicus still accounts for only 10% of the US total addressable market. The company still trades on an extravagant price-earnings multiple, which implies that this 10% will become a much bigger number in the near future. 'We don't have a fixed target in mind, our aim is to get as big a percentage market share as possible,' Hupert says. 'Importantly, we do not see any technical or capacity-related reason why we will not continue to increase our market share materially from here.' Hupert says the company's recent $10 million loan facility to lung imager 4D Medical (ASX:4DX) related to the companies AI capabilities. There's the prospect of adding one or morr 4D products to the Pro Medicus stable. "But I wouldn't read more into it than that." Broker RBC says while the result was broadly in line with consensus, the company pleased with its free cash flow generation and upbeat outlook on contracts. RBC has a 'hold' rating on the stock with a 'price target' of $350. Starpharma shares take a run Starpharma (ASX:SPL) CEO Cheryl Maley's prezzo to Bioshares annual summit in Hobart last week appears to have been enough to spark a 50% share run. The contents weren't new, but Maley did outline how management had tweaked the company's strategy over the last year. Maley started in January 2024. Otherwise, Starpharma's June quarterly report showed customer receipts of $2 million, 51% higher than the March quarter. Net cash outflows were $2 million. Starpharma's reason for being is its dendrimer enhanced product (DEP) platform, which has produced the commercialised bacterial vaginosis treatment Vivagel and the germ-busting nasal spray Viraleze. Before you ask, dendrimers are nanoscale polymers aimed at improving drug efficacy and reducing side effects (such as bone marrow toxicity and hair loss). The company has oncology programs that combine the dendrimer with three existing drugs. They are irinotecan (colorectal cancer), cabazitaxel (prostate cancer and others). Management is attempting to outlicense these assets. Maley says despite considerable interest 'the licensing process has taken longer than anticipated.' She attributes this to factors including "the evolving oncology landscape shifting towards targeted treatment options and the current geo-political environment, which has impacted the biotechnology industry at large". Starpharma ended the quarter with cash of $15.5 million – enough funding for close to two years – with an expected $3.5 million R&D tax rebate yet to come. Starpharma shares today had a well-earned rest, falling around 10%. Rhythm limbers up for raising Rhythm Biosciences (ASX:RHY) shares are on trading halt pending a capital raising announcement, on or before next Monday. It's not a bad time for the company to tap the market, given its shares have gained 75% over the last month. Rhythm is developing Colostat, a blood-based cancer assay which could replace the commonly used 'poo' tests. The company also owns Genetype, a genetic risk assessment testing platform combining clinical, family history and genetic data. Rhythm bought this asset from the administrators of Genetic Technologies. Tetratherix gets a grant Of course, the best form of funding is the free variety and the recently listed Tetratherix (ASX:TTX) has come up trumps in this regard. The wound-care house has been awarded $3.3 million of non-dilutive funding, under the federal Industry Growth Program grant. Tetratherix is commercialising products based on its polymer biomaterials, which offer claimed benefits such as increased flexibility and bioresorbability. The grant will partly fund a $7.4 million project to take its Tetramatrix platform global, including expanding its production facility near Sydney Airport. The funding spans the current financial year and 2026-27. Tetratherix shares have gained a sprightly 40% since listing on June 30, the only local life sciences IPOs year to date. But if you think that's a drought, there been no US biotech IPO for six months. The last one was diseases specialist Aardvark Therapeutics, which listed on the Nasdaq in mid-February.
News.com.au
2 hours ago
- News.com.au
Scientists find surprising sex reversal in Australian birds
Scientists have documented a surprising rate of sex reversal in wild Australian birds, a phenomenon that could be explained by rising pollution or other environmental triggers. A study of five common Australian species, including kookaburras, magpies and lorikeets, found around six percent of birds had the chromosomes of one sex but the reproductive organs of another. The findings indicated a surprisingly high number of birds had reversed their sex after birth, said researchers from the University of the Sunshine Coast. "This indicates that sex determination in wild birds is more fluid than we thought, and can persist into adulthood," said study co-author Dominique Potvin. The study performed DNA tests on almost 500 birds. The overwhelming majority of sex reversals involved genetically female birds growing male gonads. "We also discovered a genetically male kookaburra who was reproductively active with large follicles and a distended oviduct, indicating recent egg production," said Potvin. Sex reversal is well known in certain species of reptile and fish but is thought to be rare in wild birds and mammals. Scientists have documented how pollutants and even warm temperatures can trigger sex reversal in frogs. The cause of sex reversal in wild birds was not clear, the University of the Sunshine Coast study said. But it could be due to environmental factors, such as hormone-disrupting chemicals building up in wild areas. "Understanding how and why sex reversal occurs is vital for conservation and for improving the accuracy of bird research," added Potvin. The study was published this week in peer-reviewed journal Biology Letters. sft/tc
